

Evonik Financials & ESG KPI's

Financial KPI Group	P. 2
ESG KPI Group	P. 3
Division KPI	P. 4-8
Group Income Statement	P. 9-10
Group Balance Sheet	P. 11
Group Cash Flow Statement	P. 12
Group Net Financial Position	P. 13
Definitions	P. 14

As of Q3 2021 (04 November, 2021)

Financial KPI Group

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
External Sales	14.383	13.267	3.287	3.306	3.232	3.284	13.108	3.243	2.827	2.917	3.212	12.199	3.358	3.636	3.871
Growth (%)	13%	4%	1%	-3%	-3%	1%	-1%	-1%	-14%	-10%	-2%	-7%	4%	29%	33%
Volumes (%)	3%	1%	0%	-2%	-3%	0%	-1%	-1%	-12%	-5%	5%	-3%	5%	22%	16%
Prices (%)	2%	5%	1%	0%	-2%	-4%	-2%	-2%	-3%	-2%	-4%	-3%	3%	10%	15%
Exchange Rates (%)	-1%	-3%	0%	-1%	2%	1%	1%	0%	0%	-4%	-3%	-2%	-4%	-5%	0%
Other (incl. M&A; %)	9%	1%	0%	0%	0%	4%	1%	2%	1%	1%	0%	1%	0%	2%	2%
Adjusted EBITDA ¹	2.357	2.150	539	566	543	505	2.153	513	456	519	418	1.906	588	649	645
Margin (%)	16,4%	16,2%	16,4%	17,1%	16,8%	15,4%	16,4%	15,8%	16,1%	17,8%	13,0%	15,6%	17,5%	17,8%	16,7%
EBIT	1.225	1.049	296	319	219	252	1.086	247	188	245	139	819	308	380	373
Adjusted EBIT	1.486	1.361	315	340	293	253	1.201	273	202	269	146	890	336	398	387
Margin (%)	10,3%	10,3%	9,6%	10,3%	9,1%	7,7%	9,2%	8,4%	7,1%	9,2%	4,5%	7,3%	10,0%	10,9%	10,0%
Adjusted EPS	2,16	2,18	0,53	0,49	0,42	0,50	1,94	0,39	0,34	0,40	0,24	1,37	0,51	0,54	0,58
Free Cash Flow ²	511	526	159	-64	321	300	717	113	96	312	259	780	312	101	524
Cash Conversion Rate ³	22%	24%					33%					41%			
Capex (Cash outflow for investment in intangible assets, pp&e)	1.040	948	175	182	210	313	880	184	189	223	360	956	182	171	177
Capital employed (annual average)	13.257	13.299					14.035					14.600			
ROCE (%) ⁴	11,2%	10,2%					8,6%					6,1%			
Dividend (€)	1,15	1,15					1,15					1,15			
Employees (continuing operations)	36.523	32.623	32.522	32.370	32.570	32.423	32.423	32.770	32.621	32.822	33.106	33.106	32.745	32.661	32.891

¹ as from FY2018: continuing operations (excl. Methacrylates business); ² Excl. extraordinary carve out taxes of -€245m in FY 2019 (MMA divestment); ³ Free cash flow conversion = FCF/adj. EBITDA;

⁴ ROCE¹ stated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

KPI Environment, Social, Governance

	2018 FY	2019 FY	2020 FY
Strategy & Growth			
<i>Sales share with "Next Generation Solutions"</i>		>30%	35%
<i>Value added in € million</i>	4.740	5.994	4.067
Governance & Compliance			
<i>Women at the first management level below the executive board</i>	27,3%	26,1%	26,9%
<i>Women at the second management level below the executive board</i>	20,0%	24,1%	26,3%
<i>Training rate antitrust law</i>	74%	82%	88%
<i>Training rate fighting corruption</i>	83%	91%	88%
<i>Training rate code of conduct</i>	77%	89%	89%
<i>Internal investigations</i>	90	113	130
<i>Disciplinary measures</i>	106	60	110
Value Chain & Products			
<i>Procurement volume (in € billion)</i>	9,9	9,4	8,0
<i>Production output (million metric tons)</i>	11,03	9,16	8,93
<i>Use of renewable resources in production</i>	9,7%	7,9%	8,5%
<i>Raw material suppliers covered by TfS assessments</i>		66%	73%
<i>No. of sustainability audits (Evonik/TfS)</i>	380	335	289
<i>No. of sustainability assessments (Evonik/TfS)</i>	1,621	1,160	1.334
<i>R&D expenses (€ million)</i>	459	428	433
The environment			
<i>Scope 1 greenhouse gas emissions (thousands metric tons CO₂)</i>	5.689	4.923	4.802
<i>Scope 2 greenhouse gas emissions (thousands metric tons CO₂)</i>	882	563	555
<i>Scope 3 greenhouse gas emissions (million metric tons CO₂)</i>	21.0	17,8	17,7
<i>% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO₂) vs 2008</i>	-31	-42	-44
<i>Total water intake (in million m³)</i>	490,2	523,6	544,4
<i>Specific water intake (in m³ freshwater / metric ton production)</i>	31.8	32.1	34,1
<i>Production waste (thousand metric tons)</i>	393	325	290
Employees			
<i>Early employee turnover</i>	0.9%	0.9%	1,3%
<i>Continuing professional development per employee (hours)</i>	16	8	12
<i>Women in management (circles 1-3)</i>	24,3%	25,2%	26,1%
Safety			
<i>Occupational health performance index</i>	5,5	5,5	5,4
<i>Accident frequency rate (no. of accidents / 1 million working hours)</i>	0.87	1.18	0,80
<i>Incident frequency rate (no. of accidents / 1 million working hours)</i>	1,08	1,10	1,45

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

Specialty Additives

in € million	2017 FY ¹	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	3,244	3,380	842	867	861	810	3,381	852	747	777	848	3,225	907	922	934
Growth (%)	53%	4%	1%	-3%	2%	0%	0%	1%	-14%	-10%	5%	-5%	6%	23%	20%
Volumes (%)	4%	3%	-1%	-4%	1%	-1%	-1%	1%	-15%	-6%	9%	-3%	10%	24%	12%
Prices (%)	2%	3%	1%	2%	-1%	0%	1%	0%	1%	0%	-1%	0%	-1%	3%	7%
Exchange Rates (%)	-1%	-2%	1%	-1%	2%	1%	0%	0%	0%	-4%	-3%	-2%	-3%	-4%	1%
Other (incl. M&A; %)	48%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Adjusted EBITDA	857	908	225	226	232	203	886	239	202	214	201	857	273	242	224
Margin (%)	26,4%	26,9%	26,7%	26,1%	26,9%	25,1%	26,2%	28,1%	27,0%	27,5%	23,7%	26,6%	30,1%	26,2%	24,0%
EBIT	n.a.	n.a.	184	184	187	157	712	196	160	171	156	683	230	200	179
Adjusted EBIT	676	744	184	184	189	158	716	196	158	171	156	681	230	198	181
Margin (%)	20,8%	22,0%	21,9%	21,2%	22,0%	19,5%	21,2%	23,0%	21,2%	22,0%	18,4%	21,1%	25,4%	21,5%	19,4%
Capital expenditures	92	75	16	21	26	46	108	13	19	21	41	93	12	18	20
Capital employed (annual average)	3,494	3,912					4,396					4,218			
ROCE (%) ²	19,4%	19,0%					16,3%					16,1%			
Employees	n.a.	n.a.	3,646	3,642	3,665	3,651	3,651	3,631	3,610	3,649	3,666	3,666	3,678	3,680	3,704

¹ First-time consolidation of acquired Air Products businesses as of 3 January 2017. Impact on sales: -USD1.1 bn; adj. EBITDA: -USD240 m

² ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

Nutrition & Care

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	3.002	3.036	731	719	726	747	2.922	748	742	715	787	2.992	780	838	931
Growth (%)	-5%	1%	0%	-7%	-5%	-2%	-4%	2%	3%	-2%	5%	2%	4%	13%	30%
Volumes (%)	4%	5%	8%	-1%	-4%	2%	1%	3%	1%	-2%	8%	2%	1%	13%	19%
Prices (%)	-12%	1%	-7%	-5%	-3%	-5%	-1%	-1%	4%	8%	3%	4%	10%	5%	11%
Exchange Rates (%)	-1%	-5%	-1%	-1%	2%	1%	0%	0%	-2%	-8%	-7%	-4%	-7%	-5%	0%
Other (incl. M&A; %)	4%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%	0%	0%	0%	0%
Sales Animal Nutrition	1.564	1.574	374	353	345	365	1.438	398	384	330	362	1.474	404	417	461
Sales Health & Care	1.438	1.462	357	365	381	381	1.484	350	358	385	425	1.518	376	421	470
Adjusted EBITDA	498	550	113	121	119	109	462	118	168	140	133	560	143	183	192
Margin (%)	16,6%	18,1%	15,5%	16,8%	16,4%	14,6%	15,8%	15,8%	22,6%	19,6%	16,9%	18,7%	18,3%	21,8%	20,6%
EBIT	n.a.	n.a.	63	68	43	33	207	54	104	59	69	285	78	120	115
Adjusted EBIT	319	362	64	71	52	44	231	54	106	79	63	301	78	122	127
Margin (%)	10,6%	11,9%	8,8%	9,9%	7,2%	5,9%	7,9%	7,2%	14,2%	11,0%	8,0%	10,1%	10,0%	14,6%	13,6%
Capital expenditures	338	442	35	65	45	69	214	18	24	36	60	139	22	34	30
Capital employed (annual average)	2.664	2.808					3.974					3.905			
ROCE (%) ¹	12,0%	12,9%					5,8%					7,7%			
Employees	n.a.	n.a.	5.427	5.410	5.339	5.322	5.322	5.280	5.271	5.257	5.295	5.295	5.281	5.323	5.386

¹ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

Smart Materials

in € million	2017 FY ¹	2018 FY ²	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	3,148	3,382	857	845	833	836	3,371	858	722	790	866	3,235	909	975	1,002
Growth (%)	1%	7%	4%	-2%	-1%	-3%	0%	0%	-15%	-5%	4%	-4%	6%	35%	27%
Volumes (%)	7%	-3%	-3%	-5%	-5%	-6%	-4%	-4%	-20%	-7%	4%	-7%	9%	33%	18%
Prices (%)	1%	7%	7%	4%	3%	-1%	3%	-1%	0%	-2%	-1%	-1%	-1%	0%	6%
Exchange Rates (%)	-1%	-2%	0%	0%	1%	1%	0%	0%	0%	-4%	-3%	-2%	-4%	-4%	0%
Other (incl. M&A; %)	-6%	5%	0%	-1%	0%	3%	1%	5%	5%	8%	4%	6%	2%	6%	3%
Sales Inorganics	2,117	2,325	585	576	567	584	2,312	597	528	566	623	2,315	631	686	700
Sales Polymers	1,031	1,057	272	269	266	252	1,059	260	193	224	243	920	278	289	302
Adjusted EBITDA	565	631	162	164	157	168	651	166	102	137	124	529	173	176	177
Margin (%)	17,9%	18,7%	18,9%	19,4%	18,8%	20,1%	19,3%	19,3%	14,1%	17,3%	14,3%	16,4%	19,0%	18,1%	17,7%
EBIT	n.a.	n.a.	107	107	102	128	443	90	30	63	43	226	101	103	102
Adjusted EBIT	415	434	110	112	99	112	433	108	34	73	55	270	108	111	111
Margin (%)	13,2%	12,8%	12,8%	13,3%	11,9%	13,4%	12,8%	12,6%	4,7%	9,2%	6,4%	8,3%	11,9%	11,4%	11,1%
Capital expenditures	286	243	36	53	72	142	303	83	98	105	180	466	59	87	78
Capital employed (annual average)	2,226	2,565					3,651					4,223			
ROCE (%) ³	18,6%	16,9%					11,9%					6,4%			
Employees	n.a.	n.a.	7,141	7,154	7,145	7,065	7,065	7,615	7,607	7,610	7,874	7,874	7,783	7,765	7,731

¹ First-time consolidation of acquired Huber business as of 1 September 2017 (FY 2016 sales: ~USD300 m; adj. EBITDA: ~USD60 m)

² First-time consolidation of acquired PeroxyChem business as of 3 February 2020 (FY 2019 sales: ~USD300 m; adj. EBITDA: ~USD64 m); First-time consolidation of Porocel business as of 3 November 2020 (FY 2019 sales: ~USD100 m; adj. EBITDA: ~USD23 m)

³ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

Performance Materials

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	2.609	2.789	677	698	607	652	2.634	584	437	444	517	1.983	580	708	784
<i>Growth (%)</i>	11%	7%	-3%	-2%	-17%	0%	-6%	-14%	-37%	-27%	-21%	-25%	-1%	62%	77%
<i>Volumes (%)</i>	-2%	-1%	-2%	0%	-5%	8%	0%	-6%	-17%	-7%	-1%	-8%	-2%	20%	19%
<i>Prices (%)</i>	14%	9%	0%	-2%	-10%	-15%	-7%	-8%	-20%	-20%	-20%	-17%	7%	50%	58%
<i>Exchange Rates (%)</i>	-1%	-2%	0%	0%	1%	2%	1%	0%	0%	0%	0%	0%	-6%	-8%	-1%
<i>Other (incl. M&A; %)</i>	0%	1%	-1%	0%	-3%	5%	0%	0%	0%	0%	0%	0%	0%	0%	1%
Adjusted EBITDA	290	243	63	84	49	53	248	18	12	28	30	88	42	99	97
<i>Margin (%)</i>	11,1%	8,7%	9,3%	12,0%	8,1%	8,1%	9,4%	3,1%	2,7%	6,3%	5,8%	4,4%	7,2%	14,0%	12,4%
EBIT	n.a.	n.a.	16	51	16	17	101	-12	-21	-5	-9	-48	10	67	60
Adjusted EBIT	201	158	26	52	17	22	117	-12	-21	-5	-6	-45	10	66	63
<i>Margin (%)</i>	7,7%	5,7%	3,8%	7,4%	2,8%	3,4%	4,4%	-2,1%	-4,8%	-1,1%	-11,6%	-2,3%	1,7%	9,3%	8,0%
Capital expenditures	92	57	12	14	11	18	55	10	9	11	19	49	8	11	14
Capital employed (annual average)	818	919					1.296					1.290			
ROCE (%) ¹	24,5%	17,2%					9,0%					-3,5%			
Employees	n.a.	n.a.	1.653	1.640	1.669	1.645	1.645	1.815	1.811	1.799	1.798	1.798	1.810	1.791	1.962

¹ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

Technology & Infrastructure (T&I)/Other

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	712	680	180	177	205	239	800	201	179	191	194	764	182	193	220
Growth (%)	2%	-4%					18%	12%	1%	-7%	-18%	-4%	-9%	8%	15%
Adjusted EBITDA	-238	-182	-24	-29	-14	-28	-94	-28	-28	0	-70	-128	-43	-51	-45
EBIT	n.a.	n.a.	-74	-91	-129	-83	-377	-81	-85	-43	-120	-327	-111	-110	-83
Adjusted EBIT	-378	-336	-69	-79	-64	-83	-296	-73	-75	-49	-122	-317	-90	-99	-95
Capital expenditures	173	151	25	33	43	60	162	74	43	43	88	248	29	43	40
Employees	n.a.	n.a.	14.655	14.523	14.752	14.740	14.740	14.429	14.322	14.507	14.473	14.473	14.193	14.102	14.108

Group Income Statement

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	14.383	13.267	3.287	3.306	3.232	3.284	13.108	3.243	2.827	2.917	3.212	12.199	3.358	3.636	3.871
Cost of sales	-9.905	-9.271	-2.312	-2.332	-2.343	-2.427	-9.413	-2.324	-2.002	-2.104	-2.402	-8.833	-2.368	-2.550	-2.802
Gross profit on sales	4.478	3.996	975	974	889	857	3.695	919	825	813	810	3.366	990	1.086	1.069
Selling expenses	-1.695	-1.563	-380	-385	-370	-376	-1.511	-394	-368	-350	-386	-1.498	-390	-416	-436
Research and development expenses	-476	-437	-107	-101	-107	-113	-428	-109	-103	-104	-116	-433	-104	-111	-118
General administrative expenses	-714	-599	-148	-136	-135	-149	-568	-125	-128	-121	-128	-502	-132	-123	-145
Other operating income & expenses	-378	-358	-34	-38	-60	25	-107	-49	-40	1	-43	-129	-58	-58	1
Result from investments recognized at equity	10	10	-10	5	2	8	5	5	2	6	2	15	2	2	2
Income before financial result and income taxes, continuing operations = EBIT	1.225	1.049	296	319	219	252	1.086	247	188	245	139	819	308	380	373
Financial Result	-203	-155	-54	-52	-7	-19	-132	-50	-25	-24	-36	-135	-21	-40	-37
Income before income taxes, continuing operations	1.022	894	242	267	212	233	954	197	163	221	103	684	287	340	336
Income taxes	-292	-186	-27	-74	-54	-26	-180	-57	-34	-69	-20	-181	-88	-113	-100
Income after taxes, continuing operations	730	708	215	193	158	207	774	140	129	152	83	503	199	227	236
Income after taxes, discontinued operations	0	246	29	40	1.326	-43	1.353	-6	-11	-	-7	-24	-7	-3	4
Income after taxes	730	954	244	233	1.484	164	2.127	134	118	152	76	479	192	224	240
thereof attributable to non-controlling interests	17	22	5	5	5	4	21	4	4	3	3	14	6	6	5
Shareholders of EVONIK Industries AG (net income)	713	932	239	228	1.479	160	2.106	130	114	149	73	465	186	218	235
EPS	1,53	2,00	0,51	0,49	3,17	0,34	4,52	0,28	0,24	0,32	0,16	1,00	0,40	0,47	0,50

Group Adjusted Income Statement

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Sales	14.383	13.267	3.287	3.306	3.232	3.284	13.108	3.243	2.827	2.917	3.212	12.199	3.358	3.636	3.871
Adjusted EBITDA	2.357	2.150	539	566	543	505	2.153	513	456	519	418	1.906	588	649	645
Depreciation and amortization	-871	-789	-224	-226	-250	-252	-952	-240	-254	-250	-272	-1.016	-252	-251	-258
Adjusted EBIT	1.486	1.361	315	340	293	253	1.201	273	202	269	146	890	336	398	387
Adjusted net financial result	-176	-151	-53	-51	-63	-19	-185	-51	-25	-34	-36	-146	-21	-50	-37
Depreciation and amortization on intangible assets	129	143	32	33	35	36	136	33	38	38	40	149	36	35	37
Adjusted Income before income taxes, continuing operations	1.439	1.353	294	322	265	270	1.152	255	215	273	150	893	351	383	387
Adjusted income taxes, continuing operations	-415	-317	-40	-90	-65	-34	-229	-70	-51	-84	-34	-239	-106	-124	-113
Adjusted income after taxes	1.024	1.036	254	232	200	236	923	185	164	189	116	654	245	259	274
Adjusted non-controlling interest	-17	-22	-5	-5	-5	-5	-21	-4	-4	-3	-2	-14	-6	-6	-5
Adjusted net income	1.007	1.014	249	227	195	231	902	181	160	186	114	640	239	253	269
Adjusted EPS	2,16	2,18	0,53	0,49	0,42	0,50	1,94	0,39	0,34	0,40	0,24	1,37	0,51	0,54	0,58

Adjustments

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Restructuring	-25	-204	-4	-8	-6	0	-18	-1	-3	-25	15	-14	-3	-10	-5
Impairment losses/reversal of impairment losses	-82	7	-13	0	-34	0	-47	0	0	-2	6	4	0	0	0
Acquisition / divestment of shareholdings	-89	-31	-4	-4	-17	-5	-30	-22	-1	-9	-5	-37	-4	-2	-5
Other	-65	-84	2	-9	-17	4	-20	-3	-10	12	-23	-24	-21	-6	-4
=Adjustments	-261	-312	-19	-21	-74	-1	-115	-26	-14	-24	-7	-71	-28	-18	-14

Group Balance Sheet

Assets

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 FY	2021 Q1	2021 Q2	2021 Q3
Intangible assets	6.105	6.134	5.909	5.828	5.955	5.858	6.241	6.068	5.904	5.877	5.990	5.891	5.982
Property, plant and equipment	6.495	6.785	6.309	6.287	6.349	6.435	6.589	6.568	6.492	6.588	6.630	6.648	6.707
Right of use assets (capitalized leasing)			608	601	595	640	691	667	643	668	661	640	623
Investments recognized at equity	47	46	37	39	42	45	55	73	76	75	81	78	80
Financial assets	327	233	225	234	223	625	516	556	571	607	566	578	559
Deferred tax assets	1.226	1.419	1.340	1.568	1.947		1.694	1.719	1.792	2.004	1.793	1.715	1.641
Other income tax assets	14	16	15	12	10		12	12	13	13	14	14	15
Other receivables	296	56	49	49	53	82	82	116	119	102	102	127	160
Non-current assets	14.510	14.689	14.492	14.618	15.174	15.415	15.880	15.779	15.610	15.934	15.837	15.691	15.767
Inventories	2.038	2.304	2.096	2.090	2.087	1.884	1.983	2.080	1.965	1.806	1.996	2.151	2.351
Other income tax assets	154	180	182	194	217	325	334	215	148	211	198	200	135
Trade accounts receivable	1.755	1.686	1.716	1.644	1.653	1.569	1.678	1.464	1.455	1.455	1.721	1.799	1.877
Other receivables	313	295	290	332	447	387	437	301	283	231	304	346	353
Financial assets	166	140	114	88	1.298	1.278	1.141	944	766	697	435	295	379
Cash and cash equivalents	1.004	988	1.079	529	1.532	1.165	999	864	1.043	563	936	520	821
Current assets	5.430	5.593	5.477	4.897	7.234	6.608	6.572	5.868	5.660	4.963	5.590	5.311	5.916
Assets held for sale	0	0	1.554	1.588	0	0	0	0	0	0	0	0	0
Current assets	5.430	5.593	7.031	6.485	7.234	6.608	6.572	5.868	5.660	4.963	5.590	5.311	5.916
Total assets	19.940	20.282	21.523	21.103	22.408	22.023	22.452	21.647	21.170	20.897	21.427	21.002	21.683

Liabilities

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 FY	2021 Q1	2021 Q2	2021 Q3
Issued capital	466	466	466	466	466	466	466	466	466	466	466	466	466
Reserves	6.965	7.263	7.427	6.906	7.970	8.504	8.675	8.331	7.828	7.546	8.449	8.216	8.698
Equity attributable to shareholders of Evonik Industries AG	7.431	7.729	7.893	7.372	8.436	8.970	9.141	8.797	8.294	8.012	8.915	8.682	9.164
Equity attributable to non-controlling interests	88	96	97	96	100	90	89	88	87	87	84	77	82
Total equity	7.519	7.825	7.990	7.468	8.536	9.060	9.230	8.885	8.381	8.099	8.999	8.759	9.246
Provisions for pensions and other post-employment benefits	3.817	3.732	3.447	3.804	4.640	3.967	3.787	3.994	4.274	4.618	3.879	3.770	3.569
Other provisions	788	855	815	800	814	779	773	774	765	715	641	673	679
Deferred tax liabilities	541	557	494	500	494	537	555	523	552	586	580	582	591
Other income tax liabilities	225	223	246	267	431	320	298	309	315	275	253	261	260
Financial liabilities	3.706	3.689	4.187	4.181	3.660	3.713	3.171	3.628	3.595	3.564	3.592	3.553	3.631
Other payables	57	47	73	73	88	93	111	110	134	114	117	112	138
Non-current liabilities	9.134	9.103	9.262	9.625	10.127	9.409	8.695	9.338	9.635	9.872	9.062	8.951	8.868
Other provisions	968	1.047	1.042	684	749	778	824	603	644	744	815	626	789
Other income tax liabilities	50	64	62	43	106	59	71	53	136	209	229	266	
Financial liabilities	438	395	525	589	1.009	918	1.785	1.138	1.034	434	411	426	378
Trade accounts payable	1.449	1.493	1.336	1.336	1.284	1.324	1.294	1.201	1.105	1.273	1.470	1.496	1.600
Other payables	382	355	382	422	597	475	569	411	418	339	461	515	536
	3.287	3.354	3.347	3.074	3.745	3.554	4.527	3.424	3.254	2.926	3.366	3.292	3.569
Liabilities associated with assets held for sale	0	0	924	936	0	0	0	0	0	0	0	0	0
Current liabilities	3.287	3.354	4.271	4.010	3.745	3.554	4.527	3.424	3.254	2.926	3.366	3.292	3.569
Total equity and liabilities	19.940	20.282	21.523	21.103	22.408	22.023	22.452	21.647	21.170	20.897	21.427	21.002	21.683

Group Cash Flow Statement

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2020 FY	2021 Q1	2021 Q2	2021 Q3
Income before financial result and income taxes, continuing operations = EBIT	1,225	1,049	296	319	219	252	1,086	247	188	245	139	819	308	380	373
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	923	787	221	227	286	250	984	240	256	254	268	1,018	251	250	260
Result from investments recognized at equity	-10	-10	10	-5	-2	-8	-5	-5	-2	-6	-2	-15	-2	-2	-2
Gains/losses on disposal of non current assets	-73	3	-5	0	4	-12	-13	15	-5	-13	-7	-10	-1	22	0
Change in inventories	-97	-242	-65	-15	23	186	129	-90	-123	78	205	70	-158	-161	-181
Change in trade accounts receivable	-56	75	-166	40	103	64	41	-94	198	-46	-4	54	-229	-91	-62
Change in trade accounts payable and current advance payments received from customers	192	15	27	6	-123	28	-62	-18	-98	-70	156	-30	210	30	84
Change in provisions for pensions and other post-employment benefits	-202	-229	-23	-12	-34	9	-60	18	3	1	-36	-14	25	17	10
Change in other provisions	-6	158	24	-367	46	3	-294	23	-224	41	27	-133	47	-103	163
Change in miscellaneous assets/liabilities	22	26	80	-2	6	-100	-15	54	-10	39	-50	33	67	-18	40
Cash inflows/outflows from interest	-65	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash inflows from dividends	11	12	2	5	3	5	15	13	10	0	4	27	11	6	1
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-128	-117	-245	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-313	-170	-67	-78	0	-64	-209	-106	92	12	-81	-83	-35	-58	15
Cash flow from operating activities, continuing operations	1,551	1,474	334	118	403	496	1,352	297	285	535	619	1,736	494	272	701
Cash flow from operating activities, discontinued operations	0	286	25	14	52	-122	-31	0	-9	0	0	-9	0	0	0
Cash flow from operating activities	1,551	1,760	359	132	455	374	1,321	297	276	535	619	1,727	494	272	701
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-1,040	-948	-175	-182	-210	-313	-880	-184	-189	-223	-360	-956	-182	-171	-177
Cash outflows for investments in shareholdings	-4,137	-39	-10	-9	-34	-374	-427	-298	-11	-4	-161	-474	-6	0	-42
Cash outflows for loss from divestments of shareholdings	-	-	-	-	-	-	-	-	-	-	-	-	-78	-67	0
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	12	16	9	0	10	6	25	6	6	20	13	45	7	1	0
Cash inflows/outflows from divestments of businesses and other shareholdings	-10	68	0	-5	2,205	10	2,208	40	5	20	0	65	-	1	1
Cash inflows/outflows relating to securities, deposits and loans	17	-24	-13	0	-1,203	-8	-1,223	146	222	212	140	720	204	73	-99
Cash inflows from interest	-	43	4	12	5	31	52	6	8	13	3	30	2	5	3
Cash flow from investing activities, continuing operations	-5,181	-884	-185	-184	773	-648	-245	-284	41	38	-365	-570	-53	-158	-315
Cash flow from investing activities, discontinued operations	0	-89	-10	-21	-16	0	-47	0	0	0	0	0	0	0	0
Cash flow from investing activities	-5,181	-973	-195	-205	757	-648	-292	-284	41	38	-365	-570	-53	-158	-315
Cash inflows/outflows relating to capital contributions	0	2	0	1	3	0	4	3	-1	0	0	2	-	0	0
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	0	-536	-	0	-536	0	-266	-270	0	-536	0	-536	0
Cash outflows for dividends to non-controlling interests	-14	-16	-5	-5	-1	-1	-12	-6	-7	0	-3	-16	-6	-14	0
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash outflows for the purchase of treasury shares	-19	-17	-11	-6	0	0	-17	-15	-1	0	0	-16	-15	0	0
Cash inflows from the sale of treasury shares	20	13	0	13	0	0	13	0	12	0	0	12	0	12	0
Cash inflows from the addition of financial liabilities	700	61	45	172	-64	-43	110	228	631	45	135	1,039	81	3	533
Cash outflows for repayment of financial liabilities	-201	-192	-81	-72	-132	-10	-295	-356	-778	-170	-852	-2,156	-129	-56	-573
Cash inflows/outflows in connection with financial transactions	73	8	-1	16	-6	-10	-1	-8	-15	23	14	14	12	77	-5
Cash outflows for interest	-	-121	-18	-44	-19	-33	-114	-15	-23	-12	-27	-77	-16	-18	-38
Cash flow from financing activities, continuing operations	23	-798	-71	-461	-219	-97	-848	-169	-448	-384	-733	-1,734	-73	-532	-83
Cash flow from financing activities, discontinued operations	0	-3	-2	-2	-4	0	-8	0	0	0	0	0	0	0	0
Cash flow from financing activities	23	-801	-73	-463	-223	-97	-856	-169	-448	-384	-733	-1,734	-73	-532	-83
Change in cash and cash equivalents	-3,607	-14	91	-536	989	-371	173	-156	-131	189	-479	-577	368	-418	303
Cash and cash equivalents as of beginning of period	4,623	1,004	988	1,085	540	1,532	988	1,165	999	864	1,043	1,165	563	936	520
Change in cash and cash equivalents	-3,607	-14	91	-536	989	-371	173	-156	-131	189	-479	-577	368	-418	303
Changes in exchange rates and other changes in cash and cash equivalents	-12	-2	6	-9	3	4	-10	-4	-10	-1	-25	5	2	-2	-2
Cash and cash equivalents as of end of period	1,004	988	1,085	540	1,532	1,165	1,165	999	864	1,043	563	563	936	520	821
Cash and cash equivalents included in assets held for sale	0	0	-6	-11	0	0	0	0	0	0	0	0	0	0	0
Cash and cash equivalents as on the balance sheet as of end of period	1,004	988	1,079	529	1,532	1,165	1,165	999	864	1,043	563	563	936	520	821

Group Net Financial Position

in € million	2017 FY	2018 FY	2019 Q1	2019 Q2	2019 Q3	2019 FY	2020 Q1	2020 Q2	2020 Q3	2020 FY	2021 Q1	2021 Q2	2021 Q3	Notes of the annual report 2020
Non-current financial liabilities	-3.694	-3.683	-4.180	-4.179	-3.654	-3.712	-3.169	-3.627	-3.593	-3.564	-3.588	-3.549	-3.627	(6.12)
Current financial liabilities	-351	-230	-343	-458	-825	-806	-1.661	-1.063	-980	-368	-326	-337	-235	(6.12)
Financial debt	-4.045	-3.913	-4.523	-4.637	-4.479	-4.518	-4.830	-4.690	-4.573	-3.932	-3.914	-3.886	-3.862	
- Cash and cash equivalents	1.004	988	1.079	529	1.532	1.165	999	864	1.043	563	936	520	821	(7)
- Current securities	9	8	8	7	1.188	1.203	1.031	820	609	466	254	196	300	
- Other financial assets	9	10	17	20	25	9	22	12	11	17	20	0	0	
Financial assets	1.022	1.006	1.104	556	2.745	2.377	2.052	1.696	1.663	1.046	1.210	716	1.121	
Net financial debt/cash as stated on the balance sheet	-3.023	-2.907	-3.419	-4.081	-1.734	-2.141	-2.778	-2.994	-2.910	-2.886	-2.704	-3.170	-2.741	
Net financial debt/cash, discontinued operations			-18	-12	1									
Net financial debt/cash including discontinued operations		-2.907	-3.437	-4.093	-1.734	-2.141	-2.778	-2.994	-2.910	-2.866	-2.704	-3.170	-2.741	

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TFS Assessments	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.